 [1m([0morchestrator-hip fracture-BACTRIM[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes BACTRIM increase or decrease the risk of hip fracture?[0m
 [1m([0morchestrator-hip fracture-BACTRIM[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-hip fracture-BACTRIM[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-hip fracture-BACTRIM[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does BACTRIM increase or decrease the risk of hip fracture?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-hip fracture-BACTRIM[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes BACTRIM increase or decrease the risk of hip fracture?[0m
 [1m([0morchestrator-hip fracture-BACTRIM[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-hip fracture-BACTRIM[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-hip fracture-BACTRIM[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes BACTRIM increase or decrease the risk of hip fracture?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does BACTRIM increase or decrease the risk of hip fracture?"[0m[32m,[0m
[32m    [0m[32m"filter_drugs"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"BACTRIM"[0m
[32m    [0m[1;32m][0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Below are some relevant extracts for your query:[0m
[31m        -----[0m
[31m        [0m
[31mCONTENT: BACTRIM: geriatric_use: Geriatric Use Clinical studies of BACTRIM did not include sufficient numbers of subjects aged [0m[1;31m65[0m[31m and over to determine whether they respond differently from younger [0m
[31msubjects. There may be an increased risk of severe adverse reactions in elderly patients, particularly when complicating conditions exist, e.g., impaired kidney and/or liver function, possible folate [0m
[31mdeficiency, or concomitant use of other drugs. Severe skin reactions, generalized bone marrow suppression [0m[1;31m([0m[31msee WARNINGS and ADVERSE REACTIONS sections[0m[1;31m)[0m[31m, a specific decrease in platelets [0m[1;31m([0m[31mwith or [0m
[31mwithout purpura[0m[1;31m)[0m[31m, and hyperkalemia are the most frequently reported severe adverse reactions in elderly patients. In those concurrently receiving certain diuretics, primarily thiazides, an increased [0m
[31mincidence of thrombocytopenia with purpura has been reported. Increased digoxin blood levels can occur with concomitant BACTRIM therapy, especially in elderly patients. Serum digoxin levels should be [0m
[31mmonitored. BACTRIM: geriatric_use: Hematological changes indicative of folic acid deficiency may occur in elderly patients. These effects are reversible by folinic acid therapy. Appropriate dosage [0m
[31madjustments should be made for patients with impaired kidney function and duration of use should be as short as possible to minimize risks of undesired reactions [0m[1;31m([0m[31msee DOSAGE AND ADMINISTRATION [0m
[31msection[0m[1;31m)[0m[31m. The trimethoprim component of BACTRIM may cause hyperkalemia when administered to patients with underlying disorders of potassium metabolism, with renal insufficiency or when given [0m
[31mconcomitantly with drugs known to induce hyperkalemia, such as angiotensin converting enzyme inhibitors. Close monitoring of serum potassium is warranted in these patients. Discontinuation of BACTRIM [0m
[31mtreatment is recommended to help lower potassium serum levels. Bactrim Tablets contain [0m[1;31m1.8[0m[31m mg sodium [0m[1;31m([0m[1;31m0.08[0m[31m mEq[0m[1;31m)[0m[31m of sodium per tablet. Bactrim DS Tablets contain [0m[1;31m3.6[0m[31m mg [0m[1;31m([0m[1;31m0.16[0m[31m mEq[0m[1;31m)[0m[31m of sodium per tablet.[0m
[31mBACTRIM: geriatric_use: Pharmacokinetics parameters for sulfamethoxazole were similar for geriatric subjects and younger adult subjects. The mean maximum serum trimethoprim concentration was higher [0m
[31mand mean renal clearance of trimethoprim was lower in geriatric subjects compared with younger subjects [0m[1;31m([0m[31msee CLINICAL PHARMACOLOGY: Geriatric Pharmacokinetics [0m[1;31m)[0m[31m.         [0m
[31mSOUR[0m[1;31mCE:BAC[0m[31mTRIM label[0m


[31mCONTENT: BACTRIM: drug_interactions_table: [0m[1;31m<[0m[1;31mtable[0m[31m [0m[31mwidth[0m[31m=[0m[31m"97[0m[31m.74%"[0m[31m><col [0m[31mwidth[0m[31m=[0m[31m"20[0m[31m%"[0m[31m/[0m[31m><col [0m[31mwidth[0m[31m=[0m[31m"28[0m[31m%"[0m[31m/[0m[31m><col [0m[31mwidth[0m[31m=[0m[31m"50[0m[31m%"[0m[31m/[0m[31m><tbody><tr><td [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m Botrule Lrule Toprule "[0m[31m [0m
[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph><content [0m[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m>[0m[1;31mDrug[0m[1;31m([0m[31ms[0m[1;31m)[0m[31m<[0m[31m/[0m[31mcontent[0m[31m><[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m Botrule Lrule Toprule "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph><content [0m
[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m>Recommendation<[0m[31m/[0m[31mcontent[0m[31m><[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m Botrule Lrule Toprule "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph><content [0m
[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m>Comments<[0m[31m/[0m[31mcontent[0m[31m><[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m Lrule Botrule "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>Diuretics<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m Lrule Botrule "[0m[31m [0m
[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>Avoid concurrent use<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31mstyleCode[0m[31m=[0m[31m" BACTRIM: drug_interactions_table: Rrule Lrule Botrule "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>In elderly patients concurrently receiving [0m
[31mcertain diuretics, primarily thiazides, an increased incidence of thrombocytopenia with purpura has been reported.<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m Lrule Botrule "[0m[31m [0m
[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>Warfarin<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m Lrule Botrule "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>Monitor prothrombin time<[0m[31m/[0m[31mparagraph[0m[31m><paragraph>and INR<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m
[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m Lrule Botrule "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>It has been reported that BACTRIM may prolong the prothrombin time in patients who are receiving the anticoagulant warfarin [0m[1;31m([0m[31ma CYP2C9 [0m
[31msubstrate[0m[1;31m)[0m[31m. BACTRIM: drug_interactions_table: This interaction should be kept in mind when BACTRIM is given to patients already on anticoagulant therapy, and the coagulation time should be [0m
[31mreassessed.<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m Lrule Botrule "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>Phenytoin<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m Lrule Botrule "[0m[31m [0m
[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>Monitor serum phenytoin levels<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m Lrule Botrule "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>BACTRIM may inhibit the hepatic metabolism of phenytoin [0m[1;31m([0m[31ma CYP2C9 [0m
[31msubstrate[0m[1;31m)[0m[31m. BACTRIM, given at a common clinical dosage, increased the phenytoin half-life by [0m[1;31m39[0m[31m% and decreased the phenytoin metabolic clearance rate by [0m[1;31m27[0m[31m%. BACTRIM: drug_interactions_table: [0m
[31m.<[0m[31m/[0m[31mparagraph[0m[31m><paragraph>When administering these drugs concurrently, one should be alert for possible excessive phenytoin effect.<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m Lrule Botrule "[0m[31m [0m
[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>Methotrexate<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m Lrule Botrule "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>Avoid concurrent use<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m Lrule Botrule[0m
[31m"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>Sulfonamides can also displace methotrexate from plasma protein binding sites and can compete with the renal transport of methotrexate, thus increasing free methotrexate [0m
[31mconcentrations. BACTRIM: drug_interactions_table: paragraph><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m Lrule Botrule "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>Cyclosporine<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m [0m
[31mLrule Botrule "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>Avoid concurrent use<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m Lrule Botrule "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph[0m[1;31m>[0m[31mThere have been reports of marked but reversible [0m
[31mnephrotoxicity with coadministration of BACTRIM and cyclosporine in renal transplant recipients.         [0m
[31mSOUR[0m[1;31mCE:BAC[0m[31mTRIM label[0m


[31mCONTENT: BACTRIM: drug_and_or_laboratory_test_interactions: Drug/Laboratory Test Interactions BACTRIM, specifically the trimethoprim component, can interfere with a serum methotrexate assay as [0m
[31mdetermined by the competitive binding protein technique [0m[1;31m([0m[31mCBPA[0m[1;31m)[0m[31m when a bacterial dihydrofolate reductase is used as the binding protein. No interference occurs, however, if methotrexate is measured by [0m
[31ma radioimmunoassay [0m[1;31m([0m[31mRIA[0m[1;31m)[0m[31m. The presence of BACTRIM may also interfere with the Jaffé alkaline picrate reaction assay for creatinine, resulting in overestimations of about [0m[1;31m10[0m[31m% in the range of normal [0m
[31mvalues.         [0m
[31mSOUR[0m[1;31mCE:BAC[0m[31mTRIM label[0m


[31mCONTENT: BACTRIM: openfda: spl_id         [0m
[31mSOUR[0m[1;31mCE:BAC[0m[31mTRIM label[0m


[31mCONTENT: BACTRIM: drug_interactions: Drug Interactions Potential for BACTRIM to Affect Other Drugs Trimethoprim is an inhibitor of CYP2C8 as well as OCT2 transporter. Sulfamethoxazole is an inhibitor [0m
[31mof CYP2C9. Avoid coadministration of BACTRIM with drugs that are substrates of CYP2C8 and 2C9 or OCT2. Table [0m[1;31m1[0m[31m: Drug Interactions with BACTRIM [0m[1;31mDrug[0m[1;31m([0m[31ms[0m[1;31m)[0m[31m Recommendation Comments Diuretics Avoid [0m
[31mconcurrent use In elderly patients concurrently receiving certain diuretics, primarily thiazides, an increased incidence of thrombocytopenia with purpura has been reported. Warfarin Monitor [0m
[31mprothrombin time and INR It has been reported that BACTRIM may prolong the prothrombin time in patients who are receiving the anticoagulant warfarin [0m[1;31m([0m[31ma CYP2C9 substrate[0m[1;31m)[0m[31m. BACTRIM: drug_interactions: [0m
[31mThis interaction should be kept in mind when BACTRIM is given to patients already on anticoagulant therapy, and the coagulation time should be reassessed. Phenytoin Monitor serum phenytoin levels [0m
[31mBACTRIM may inhibit the hepatic metabolism of phenytoin [0m[1;31m([0m[31ma CYP2C9 substrate[0m[1;31m)[0m[31m. BACTRIM, given at a common clinical dosage, increased the phenytoin half-life by [0m[1;31m39[0m[31m% and decreased the phenytoin metabolic[0m
[31mclearance rate by [0m[1;31m27[0m[31m%. When administering these drugs concurrently, one should be alert for possible excessive phenytoin effect. Methotrexate Avoid concurrent use Sulfonamides can also displace [0m
[31mmethotrexate from plasma protein binding sites and can compete with the renal transport of methotrexate, thus increasing free methotrexate concentrations. BACTRIM: drug_interactions: Cyclosporine [0m
[31mAvoid concurrent use There have been reports of marked but reversible nephrotoxicity with coadministration of BACTRIM and cyclosporine in renal transplant recipients. Digoxin Monitor serum digoxin [0m
[31mlevels Increased digoxin blood levels can occur with concomitant BACTRIM therapy, especially in elderly patients. Indomethacin Avoid concurrent use Increased sulfamethoxazole blood levels may occur in[0m
[31mpatients who are also receiving indomethacin. Pyrimethamine Avoid concurrent use Occasional reports suggest that patients receiving pyrimethamine as malaria prophylaxis in doses exceeding [0m[1;31m25[0m[31m mg weekly[0m
[31mmay develop megaloblastic anemia if BACTRIM is prescribed. Tricyclic Antidepressants [0m[1;31m([0m[31mTCAs[0m[1;31m)[0m[31m Monitor therapeutic response and adjust dose of TCA accordingly The efficacy of tricyclic antidepressants [0m
[31mcan decrease when coadministered with BACTRIM. BACTRIM: drug_interactions: Oral Hypoglycemics Monitor blood glucose more frequently Like other sulfonamide-containing drugs, BACTRIM potentiates the [0m
[31meffect of oral hypoglycemic that are metabolized by CYP2C8 [0m[1;31m([0m[31me.g., pioglitazone, repaglinide, and rosiglitazone[0m[1;31m)[0m[31m or CYP2C9 [0m[1;31m([0m[31me.g., glipizide and glyburide[0m[1;31m)[0m[31m or eliminated renally via OCT2 [0m[1;31m([0m[31me.g., [0m
[31mmetformin[0m[1;31m)[0m[31m. Additional monitoring of blood glucose may be warranted. Amantadine Avoid concurrent use In the literature, a single case of toxic delirium has been reported after concomitant intake of [0m
[31mBACTRIM and amantadine [0m[1;31m([0m[31man OCT2 substrate[0m[1;31m)[0m[31m. Cases of interactions with other OCT2 substrates, memantine and metformin, have also been reported.         [0m
[31mSOUR[0m[1;31mCE:BAC[0m[31mTRIM label[0m


[31mCONTENT: BACTRIM: precautions: Animal Data In rats, oral doses of either [0m[1;31m533[0m[31m mg/kg sulfamethoxazole or [0m[1;31m200[0m[31m mg/kg trimethoprim produced teratologic effects manifested mainly as cleft palates. These [0m
[31mdoses are approximately [0m[1;31m5[0m[31m and [0m[1;31m6[0m[31m times the recommended human total daily dose on a body surface area basis. In two studies in rats, no teratology was observed when [0m[1;31m512[0m[31m mg/kg of sulfamethoxazole was [0m
[31mused in combination with [0m[1;31m128[0m[31m mg/kg of trimethoprim. In some rabbit studies, an overall increase in fetal loss [0m[1;31m([0m[31mdead and resorbed conceptuses[0m[1;31m)[0m[31m was associated with doses of trimethoprim [0m[1;31m6[0m[31m times the [0m
[31mhuman therapeutic dose based on body surface area. Nonteratogenic Effects See CONTRAINDICATIONS section. Nursing Mothers Levels of sulfamethoxazole and trimethoprim in breast milk are approximately [0m
[1;31m2[0m[31m–[0m[1;31m5[0m[31m% of the recommended daily dose for infants over [0m[1;31m2[0m[31m months of age. BACTRIM: precautions: Caution should be exercised when BACTRIM is administered to a nursing woman, especially when breastfeeding [0m
[31mjaundiced, ill, stressed, or premature infants because of the potential risk of bilirubin displacement and kernicterus. Pediatric Use BACTRIM is contraindicated for infants younger than [0m[1;31m2[0m[31m months of [0m
[31mage [0m[1;31m([0m[31msee INDICATIONS AND USAGE and CONTRAINDICATIONS sections[0m[1;31m)[0m[31m. Geriatric Use Clinical studies of BACTRIM did not include sufficient numbers of subjects aged [0m[1;31m65[0m[31m and over to determine whether they [0m
[31mrespond differently from younger subjects. There may be an increased risk of severe adverse reactions in elderly patients, particularly when complicating conditions exist, e.g., impaired kidney and/or[0m
[31mliver function, possible folate deficiency, or concomitant use of other drugs. BACTRIM: precautions: Severe skin reactions, generalized bone marrow suppression [0m[1;31m([0m[31msee WARNINGS and ADVERSE REACTIONS [0m
[31msections[0m[1;31m)[0m[31m, a specific decrease in platelets [0m[1;31m([0m[31mwith or without purpura[0m[1;31m)[0m[31m, and hyperkalemia are the most frequently reported severe adverse reactions in elderly patients. In those concurrently receiving [0m
[31mcertain diuretics, primarily thiazides, an increased incidence of thrombocytopenia with purpura has been reported. Increased digoxin blood levels can occur with concomitant BACTRIM therapy, especially[0m
[31min elderly patients. Serum digoxin levels should be monitored. Hematological changes indicative of folic acid deficiency may occur in elderly patients. These effects are reversible by folinic acid [0m
[31mtherapy. Appropriate dosage adjustments should be made for patients with impaired kidney function and duration of use should be as short as possible to minimize risks of undesired reactions [0m[1;31m([0m[31msee [0m
[31mDOSAGE AND ADMINISTRATION section[0m[1;31m)[0m[31m. BACTRIM: precautions: The trimethoprim component of BACTRIM may cause hyperkalemia when administered to patients with underlying disorders of potassium metabolism, [0m
[31mwith renal insufficiency or when given concomitantly with drugs known to induce hyperkalemia, such as angiotensin converting enzyme inhibitors. Close monitoring of serum potassium is warranted in [0m
[31mthese patients. Discontinuation of BACTRIM treatment is recommended to help lower potassium serum levels. Bactrim Tablets contain [0m[1;31m1.8[0m[31m mg sodium [0m[1;31m([0m[1;31m0.08[0m[31m mEq[0m[1;31m)[0m[31m of sodium per tablet. Bactrim DS Tablets [0m
[31mcontain [0m[1;31m3.6[0m[31m mg [0m[1;31m([0m[1;31m0.16[0m[31m mEq[0m[1;31m)[0m[31m of sodium per tablet. Pharmacokinetics parameters for sulfamethoxazole were similar for geriatric subjects and younger adult subjects. BACTRIM: precautions: The mean maximum [0m
[31mserum trimethoprim concentration was higher and mean renal clearance of trimethoprim was lower in geriatric subjects compared with younger subjects [0m[1;31m([0m[31msee CLINICAL PHARMACOLOGY: Geriatric [0m
[31mPharmacokinetics [0m[1;31m)[0m[31m.         [0m
[31mSOUR[0m[1;31mCE:BAC[0m[31mTRIM label[0m

[31m        -----[0m
[31m        If NONE of the extracts are relevant, try doing a web search with the[0m
[31m        `relevant_search_extracts` tool/function-call[0m
[31m        [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32m DO-NOT-KNOW[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_search_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_search_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does BACTRIM increase or decrease the risk of hip fracture?"[0m[32m,[0m
[32m    [0m[32m"drug"[0m[32m: [0m[32m"BACTRIM"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_search_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31mNo relevant extracts found for Does BACTRIM increase or decrease the risk of hip [0m
[31mfracture?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m[32m DO-NOT-KNOW[0m
 [1m([0morchestrator-hip fracture-BACTRIM[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-hip fracture-BACTRIM[1m)[0m [31m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
*[1m([0morchestrator-hip fracture-BACTRIM[1m)[0m [37m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-hip fracture-BACTRIM[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-hip fracture-BACTRIM[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-hip fracture-BACTRIM[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does BACTRIM increase or decrease the risk of hip fracture?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-hip fracture-BACTRIM[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes BACTRIM increase or decrease the risk of hip fracture?[0m
 [1m([0morchestrator-hip fracture-BACTRIM[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-hip fracture-BACTRIM[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-hip fracture-BACTRIM[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes BACTRIM increase or decrease the risk of hip fracture?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_search_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_search_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does BACTRIM increase or decrease the risk of hip fracture?"[0m[32m,[0m
[32m    [0m[32m"drug"[0m[32m: [0m[32m"BACTRIM"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_search_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31mCONTENT: BACTRIM: geriatric_use: Geriatric Use Clinical studies of BACTRIM did not include sufficient numbers of subjects aged [0m[1;31m65[0m[31m and over to determine whether they respond differently from younger [0m
[31msubjects. There may be an increased risk of severe adverse reactions in elderly patients, particularly when complicating conditions exist, e.g., impaired kidney and/or liver function, possible folate [0m
[31mdeficiency, or concomitant use of other drugs. Severe skin reactions, generalized bone marrow suppression [0m[1;31m([0m[31msee WARNINGS and ADVERSE REACTIONS sections[0m[1;31m)[0m[31m, a specific decrease in platelets [0m[1;31m([0m[31mwith or [0m
[31mwithout purpura[0m[1;31m)[0m[31m, and hyperkalemia are the most frequently reported severe adverse reactions in elderly patients. In those concurrently receiving certain diuretics, primarily thiazides, an increased [0m
[31mincidence of thrombocytopenia with purpura has been reported. Increased digoxin blood levels can occur with concomitant BACTRIM therapy, especially in elderly patients. Serum digoxin levels should be [0m
[31mmonitored. BACTRIM: geriatric_use: Hematological changes indicative of folic acid deficiency may occur in elderly patients. These effects are reversible by folinic acid therapy. Appropriate dosage [0m
[31madjustments should be made for patients with impaired kidney function and duration of use should be as short as possible to minimize risks of undesired reactions [0m[1;31m([0m[31msee DOSAGE AND ADMINISTRATION [0m
[31msection[0m[1;31m)[0m[31m. The trimethoprim component of BACTRIM may cause hyperkalemia when administered to patients with underlying disorders of potassium metabolism, with renal insufficiency or when given [0m
[31mconcomitantly with drugs known to induce hyperkalemia, such as angiotensin converting enzyme inhibitors. Close monitoring of serum potassium is warranted in these patients. Discontinuation of BACTRIM [0m
[31mtreatment is recommended to help lower potassium serum levels. Bactrim Tablets contain [0m[1;31m1.8[0m[31m mg sodium [0m[1;31m([0m[1;31m0.08[0m[31m mEq[0m[1;31m)[0m[31m of sodium per tablet. Bactrim DS Tablets contain [0m[1;31m3.6[0m[31m mg [0m[1;31m([0m[1;31m0.16[0m[31m mEq[0m[1;31m)[0m[31m of sodium per tablet.[0m
[31mBACTRIM: geriatric_use: Pharmacokinetics parameters for sulfamethoxazole were similar for geriatric subjects and younger adult subjects. The mean maximum serum trimethoprim concentration was higher [0m
[31mand mean renal clearance of trimethoprim was lower in geriatric subjects compared with younger subjects [0m[1;31m([0m[31msee CLINICAL PHARMACOLOGY: Geriatric Pharmacokinetics [0m[1;31m)[0m[31m.         [0m
[31mSOUR[0m[1;31mCE:BAC[0m[31mTRIM label[0m


[31mCONTENT: BACTRIM: drug_interactions_table: [0m[1;31m<[0m[1;31mtable[0m[31m [0m[31mwidth[0m[31m=[0m[31m"97[0m[31m.74%"[0m[31m><col [0m[31mwidth[0m[31m=[0m[31m"20[0m[31m%"[0m[31m/[0m[31m><col [0m[31mwidth[0m[31m=[0m[31m"28[0m[31m%"[0m[31m/[0m[31m><col [0m[31mwidth[0m[31m=[0m[31m"50[0m[31m%"[0m[31m/[0m[31m><tbody><tr><td [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m Botrule Lrule Toprule "[0m[31m [0m
[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph><content [0m[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m>[0m[1;31mDrug[0m[1;31m([0m[31ms[0m[1;31m)[0m[31m<[0m[31m/[0m[31mcontent[0m[31m><[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m Botrule Lrule Toprule "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph><content [0m
[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m>Recommendation<[0m[31m/[0m[31mcontent[0m[31m><[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m Botrule Lrule Toprule "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph><content [0m
[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m>Comments<[0m[31m/[0m[31mcontent[0m[31m><[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m Lrule Botrule "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>Diuretics<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m Lrule Botrule "[0m[31m [0m
[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>Avoid concurrent use<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31mstyleCode[0m[31m=[0m[31m" BACTRIM: drug_interactions_table: Rrule Lrule Botrule "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>In elderly patients concurrently receiving [0m
[31mcertain diuretics, primarily thiazides, an increased incidence of thrombocytopenia with purpura has been reported.<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m Lrule Botrule "[0m[31m [0m
[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>Warfarin<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m Lrule Botrule "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>Monitor prothrombin time<[0m[31m/[0m[31mparagraph[0m[31m><paragraph>and INR<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m
[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m Lrule Botrule "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>It has been reported that BACTRIM may prolong the prothrombin time in patients who are receiving the anticoagulant warfarin [0m[1;31m([0m[31ma CYP2C9 [0m
[31msubstrate[0m[1;31m)[0m[31m. BACTRIM: drug_interactions_table: This interaction should be kept in mind when BACTRIM is given to patients already on anticoagulant therapy, and the coagulation time should be [0m
[31mreassessed.<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m Lrule Botrule "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>Phenytoin<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m Lrule Botrule "[0m[31m [0m
[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>Monitor serum phenytoin levels<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m Lrule Botrule "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>BACTRIM may inhibit the hepatic metabolism of phenytoin [0m[1;31m([0m[31ma CYP2C9 [0m
[31msubstrate[0m[1;31m)[0m[31m. BACTRIM, given at a common clinical dosage, increased the phenytoin half-life by [0m[1;31m39[0m[31m% and decreased the phenytoin metabolic clearance rate by [0m[1;31m27[0m[31m%. BACTRIM: drug_interactions_table: [0m
[31m.<[0m[31m/[0m[31mparagraph[0m[31m><paragraph>When administering these drugs concurrently, one should be alert for possible excessive phenytoin effect.<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m Lrule Botrule "[0m[31m [0m
[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>Methotrexate<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m Lrule Botrule "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>Avoid concurrent use<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m Lrule Botrule[0m
[31m"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>Sulfonamides can also displace methotrexate from plasma protein binding sites and can compete with the renal transport of methotrexate, thus increasing free methotrexate [0m
[31mconcentrations. BACTRIM: drug_interactions_table: paragraph><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m Lrule Botrule "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>Cyclosporine<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m [0m
[31mLrule Botrule "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>Avoid concurrent use<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m Lrule Botrule "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph[0m[1;31m>[0m[31mThere have been reports of marked but reversible [0m
[31mnephrotoxicity with coadministration of BACTRIM and cyclosporine in renal transplant recipients.         [0m
[31mSOUR[0m[1;31mCE:BAC[0m[31mTRIM label[0m


[31mCONTENT: BACTRIM: drug_and_or_laboratory_test_interactions: Drug/Laboratory Test Interactions BACTRIM, specifically the trimethoprim component, can interfere with a serum methotrexate assay as [0m
[31mdetermined by the competitive binding protein technique [0m[1;31m([0m[31mCBPA[0m[1;31m)[0m[31m when a bacterial dihydrofolate reductase is used as the binding protein. No interference occurs, however, if methotrexate is measured by [0m
[31ma radioimmunoassay [0m[1;31m([0m[31mRIA[0m[1;31m)[0m[31m. The presence of BACTRIM may also interfere with the Jaffé alkaline picrate reaction assay for creatinine, resulting in overestimations of about [0m[1;31m10[0m[31m% in the range of normal [0m
[31mvalues.         [0m
[31mSOUR[0m[1;31mCE:BAC[0m[31mTRIM label[0m


[31mCONTENT: BACTRIM: openfda: spl_id         [0m
[31mSOUR[0m[1;31mCE:BAC[0m[31mTRIM label[0m


[31mCONTENT: BACTRIM: drug_interactions: Drug Interactions Potential for BACTRIM to Affect Other Drugs Trimethoprim is an inhibitor of CYP2C8 as well as OCT2 transporter. Sulfamethoxazole is an inhibitor [0m
[31mof CYP2C9. Avoid coadministration of BACTRIM with drugs that are substrates of CYP2C8 and 2C9 or OCT2. Table [0m[1;31m1[0m[31m: Drug Interactions with BACTRIM [0m[1;31mDrug[0m[1;31m([0m[31ms[0m[1;31m)[0m[31m Recommendation Comments Diuretics Avoid [0m
[31mconcurrent use In elderly patients concurrently receiving certain diuretics, primarily thiazides, an increased incidence of thrombocytopenia with purpura has been reported. Warfarin Monitor [0m
[31mprothrombin time and INR It has been reported that BACTRIM may prolong the prothrombin time in patients who are receiving the anticoagulant warfarin [0m[1;31m([0m[31ma CYP2C9 substrate[0m[1;31m)[0m[31m. BACTRIM: drug_interactions: [0m
[31mThis interaction should be kept in mind when BACTRIM is given to patients already on anticoagulant therapy, and the coagulation time should be reassessed. Phenytoin Monitor serum phenytoin levels [0m
[31mBACTRIM may inhibit the hepatic metabolism of phenytoin [0m[1;31m([0m[31ma CYP2C9 substrate[0m[1;31m)[0m[31m. BACTRIM, given at a common clinical dosage, increased the phenytoin half-life by [0m[1;31m39[0m[31m% and decreased the phenytoin metabolic[0m
[31mclearance rate by [0m[1;31m27[0m[31m%. When administering these drugs concurrently, one should be alert for possible excessive phenytoin effect. Methotrexate Avoid concurrent use Sulfonamides can also displace [0m
[31mmethotrexate from plasma protein binding sites and can compete with the renal transport of methotrexate, thus increasing free methotrexate concentrations. BACTRIM: drug_interactions: Cyclosporine [0m
[31mAvoid concurrent use There have been reports of marked but reversible nephrotoxicity with coadministration of BACTRIM and cyclosporine in renal transplant recipients. Digoxin Monitor serum digoxin [0m
[31mlevels Increased digoxin blood levels can occur with concomitant BACTRIM therapy, especially in elderly patients. Indomethacin Avoid concurrent use Increased sulfamethoxazole blood levels may occur in[0m
[31mpatients who are also receiving indomethacin. Pyrimethamine Avoid concurrent use Occasional reports suggest that patients receiving pyrimethamine as malaria prophylaxis in doses exceeding [0m[1;31m25[0m[31m mg weekly[0m
[31mmay develop megaloblastic anemia if BACTRIM is prescribed. Tricyclic Antidepressants [0m[1;31m([0m[31mTCAs[0m[1;31m)[0m[31m Monitor therapeutic response and adjust dose of TCA accordingly The efficacy of tricyclic antidepressants [0m
[31mcan decrease when coadministered with BACTRIM. BACTRIM: drug_interactions: Oral Hypoglycemics Monitor blood glucose more frequently Like other sulfonamide-containing drugs, BACTRIM potentiates the [0m
[31meffect of oral hypoglycemic that are metabolized by CYP2C8 [0m[1;31m([0m[31me.g., pioglitazone, repaglinide, and rosiglitazone[0m[1;31m)[0m[31m or CYP2C9 [0m[1;31m([0m[31me.g., glipizide and glyburide[0m[1;31m)[0m[31m or eliminated renally via OCT2 [0m[1;31m([0m[31me.g., [0m
[31mmetformin[0m[1;31m)[0m[31m. Additional monitoring of blood glucose may be warranted. Amantadine Avoid concurrent use In the literature, a single case of toxic delirium has been reported after concomitant intake of [0m
[31mBACTRIM and amantadine [0m[1;31m([0m[31man OCT2 substrate[0m[1;31m)[0m[31m. Cases of interactions with other OCT2 substrates, memantine and metformin, have also been reported.         [0m
[31mSOUR[0m[1;31mCE:BAC[0m[31mTRIM label[0m


[31mCONTENT: BACTRIM: precautions: Animal Data In rats, oral doses of either [0m[1;31m533[0m[31m mg/kg sulfamethoxazole or [0m[1;31m200[0m[31m mg/kg trimethoprim produced teratologic effects manifested mainly as cleft palates. These [0m
[31mdoses are approximately [0m[1;31m5[0m[31m and [0m[1;31m6[0m[31m times the recommended human total daily dose on a body surface area basis. In two studies in rats, no teratology was observed when [0m[1;31m512[0m[31m mg/kg of sulfamethoxazole was [0m
[31mused in combination with [0m[1;31m128[0m[31m mg/kg of trimethoprim. In some rabbit studies, an overall increase in fetal loss [0m[1;31m([0m[31mdead and resorbed conceptuses[0m[1;31m)[0m[31m was associated with doses of trimethoprim [0m[1;31m6[0m[31m times the [0m
[31mhuman therapeutic dose based on body surface area. Nonteratogenic Effects See CONTRAINDICATIONS section. Nursing Mothers Levels of sulfamethoxazole and trimethoprim in breast milk are approximately [0m
[1;31m2[0m[31m–[0m[1;31m5[0m[31m% of the recommended daily dose for infants over [0m[1;31m2[0m[31m months of age. BACTRIM: precautions: Caution should be exercised when BACTRIM is administered to a nursing woman, especially when breastfeeding [0m
[31mjaundiced, ill, stressed, or premature infants because of the potential risk of bilirubin displacement and kernicterus. Pediatric Use BACTRIM is contraindicated for infants younger than [0m[1;31m2[0m[31m months of [0m
[31mage [0m[1;31m([0m[31msee INDICATIONS AND USAGE and CONTRAINDICATIONS sections[0m[1;31m)[0m[31m. Geriatric Use Clinical studies of BACTRIM did not include sufficient numbers of subjects aged [0m[1;31m65[0m[31m and over to determine whether they [0m
[31mrespond differently from younger subjects. There may be an increased risk of severe adverse reactions in elderly patients, particularly when complicating conditions exist, e.g., impaired kidney and/or[0m
[31mliver function, possible folate deficiency, or concomitant use of other drugs. BACTRIM: precautions: Severe skin reactions, generalized bone marrow suppression [0m[1;31m([0m[31msee WARNINGS and ADVERSE REACTIONS [0m
[31msections[0m[1;31m)[0m[31m, a specific decrease in platelets [0m[1;31m([0m[31mwith or without purpura[0m[1;31m)[0m[31m, and hyperkalemia are the most frequently reported severe adverse reactions in elderly patients. In those concurrently receiving [0m
[31mcertain diuretics, primarily thiazides, an increased incidence of thrombocytopenia with purpura has been reported. Increased digoxin blood levels can occur with concomitant BACTRIM therapy, especially[0m
[31min elderly patients. Serum digoxin levels should be monitored. Hematological changes indicative of folic acid deficiency may occur in elderly patients. These effects are reversible by folinic acid [0m
[31mtherapy. Appropriate dosage adjustments should be made for patients with impaired kidney function and duration of use should be as short as possible to minimize risks of undesired reactions [0m[1;31m([0m[31msee [0m
[31mDOSAGE AND ADMINISTRATION section[0m[1;31m)[0m[31m. BACTRIM: precautions: The trimethoprim component of BACTRIM may cause hyperkalemia when administered to patients with underlying disorders of potassium metabolism, [0m
[31mwith renal insufficiency or when given concomitantly with drugs known to induce hyperkalemia, such as angiotensin converting enzyme inhibitors. Close monitoring of serum potassium is warranted in [0m
[31mthese patients. Discontinuation of BACTRIM treatment is recommended to help lower potassium serum levels. Bactrim Tablets contain [0m[1;31m1.8[0m[31m mg sodium [0m[1;31m([0m[1;31m0.08[0m[31m mEq[0m[1;31m)[0m[31m of sodium per tablet. Bactrim DS Tablets [0m
[31mcontain [0m[1;31m3.6[0m[31m mg [0m[1;31m([0m[1;31m0.16[0m[31m mEq[0m[1;31m)[0m[31m of sodium per tablet. Pharmacokinetics parameters for sulfamethoxazole were similar for geriatric subjects and younger adult subjects. BACTRIM: precautions: The mean maximum [0m
[31mserum trimethoprim concentration was higher and mean renal clearance of trimethoprim was lower in geriatric subjects compared with younger subjects [0m[1;31m([0m[31msee CLINICAL PHARMACOLOGY: Geriatric [0m
[31mPharmacokinetics [0m[1;31m)[0m[31m.         [0m
[31mSOUR[0m[1;31mCE:BAC[0m[31mTRIM label[0m

 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m[32m DO-NOT-KNOW[0m
 [1m([0morchestrator-hip fracture-BACTRIM[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-hip fracture-BACTRIM[1m)[0m [31m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
*[1m([0morchestrator-hip fracture-BACTRIM[1m)[0m [37m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-hip fracture-BACTRIM[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-hip fracture-BACTRIM[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-hip fracture-BACTRIM[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does BACTRIM increase or decrease the risk of hip fracture?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-hip fracture-BACTRIM[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes BACTRIM increase or decrease the risk of hip fracture?[0m
 [1m([0morchestrator-hip fracture-BACTRIM[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-hip fracture-BACTRIM[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-hip fracture-BACTRIM[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes BACTRIM increase or decrease the risk of hip fracture?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_search_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_search_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does BACTRIM increase or decrease the risk of hip fracture?"[0m[32m,[0m
[32m    [0m[32m"drug"[0m[32m: [0m[32m"BACTRIM"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_search_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31mNo relevant extracts found for Does BACTRIM increase or decrease the risk of hip [0m
[31mfracture?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m[32m DO-NOT-KNOW[0m
 [1m([0morchestrator-hip fracture-BACTRIM[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-hip fracture-BACTRIM[1m)[0m [31m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
*[1m([0morchestrator-hip fracture-BACTRIM[1m)[0m [37m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-hip fracture-BACTRIM[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-hip fracture-BACTRIM[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-hip fracture-BACTRIM[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"final_answer"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"question"[0m[32m: [0m[32m"Does BACTRIM increase or decrease the risk of hip fracture?"[0m[32m,[0m
[32m    [0m[32m"steps"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"I asked FDAHandler whether BACTRIM increases or decreases the risk of hip fracture."[0m
[32m    [0m[1;32m][0m[32m,[0m
[32m    [0m[32m"answer"[0m[32m: [0m[32m"DO-NOT-KNOW"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-hip fracture-BACTRIM[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31m__PASS__:Critic[0m
 [1m([0morchestrator-hip fracture-BACTRIM[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-hip fracture-BACTRIM[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0morchestrator-hip fracture-BACTRIM[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"final_answer"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"question"[0m[34m: [0m[34m"Does BACTRIM increase or decrease the risk of hip fracture?"[0m[34m,[0m
[34m    [0m[34m"steps"[0m[34m: [0m[1;34m[[0m
[34m      [0m[34m"I asked FDAHandler whether BACTRIM increases or decreases the risk of hip fracture."[0m
[34m    [0m[1;34m][0m[34m,[0m
[34m    [0m[34m"answer"[0m[34m: [0m[34m"DO-NOT-KNOW"[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"final_answer"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Question: Does BACTRIM increase or decrease the risk of hip fracture?[0m
[31m        -----[0m
[31m        Reasoning:[0m
[31m        [0m[1;31m1[0m[31m. I asked FDAHandler whether BACTRIM increases or decreases the risk of hip fracture.[0m
[31m        -----[0m
[31m        Final answer: DO-NOT-KNOW[0m
[31m        [0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m
 [1m([0mCritic[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"feedback"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"critique"[0m[32m: [0m[32m"The reasoning provided does not include any information about the strength of evidence or the magnitude of the effect, which was required as per the instructions. Additionally, it [0m
[32mdoes not explain why it was not possible to answer the question beyond stating that FDAHandler responded with DO-NOT-KNOW. The response should include a rationale for the lack of information or a [0m
[32msummary of any existing evidence, even if it is inconclusive."[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m<[0m[1;31mDONE[0m[1;31m>[0m[31m __PASS__[0m
*[1m([0morchestrator-hip fracture-BACTRIM[1m)[0m [37m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>     AGENT[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"feedback"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"critique"[0m[34m: [0m[34m"The reasoning provided does not include any information about the strength of evidence or the magnitude of the effect, which was required as per the instructions. Additionally, it [0m
[34mdoes not explain why it was not possible to answer the question beyond stating that FDAHandler responded with DO-NOT-KNOW. The response should include a rationale for the lack of information or a [0m
[34msummary of any existing evidence, even if it is inconclusive."[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"feedback"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0morchestrator-hip fracture-BACTRIM[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Feedback: The reasoning provided does not include any information about the strength of evidence or the magnitude of the effect, which was required as per the instructions. Additionally, it [0m
[31mdoes not explain why it was not possible to answer the question beyond stating that FDAHandler responded with DO-NOT-KNOW. The response should include a rationale for the lack of information or a [0m
[31msummary of any existing evidence, even if it is inconclusive.[0m

[31m        If any flaws in the reasoning used to produce your[0m
[31m        answer were identified, you must try again.[0m
[31m        [0m
 [1m([0morchestrator-hip fracture-BACTRIM[1m)[0m [31m Entity.USER [0m
 [1m([0morchestrator-hip fracture-BACTRIM[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-hip fracture-BACTRIM[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mI apologize for the oversight. Let me clarify the situation.[0m

[32mThe question asked was whether BACTRIM increases or decreases the risk of hip fracture. To answer this, I reached out to FDAHandler to inquire about the relationship between BACTRIM and the risk of [0m
[32mhip fracture. However, FDAHandler's response was DO-NOT-KNOW, which indicates that the FDA label data does not specify any information regarding BACTRIM's effect on the risk of hip fracture.[0m

[32mThe lack of information from FDAHandler suggests that there is either no known association between BACTRIM and hip fracture risk according to the FDA label data, or that the data is inconclusive or [0m
[32mnot available. Therefore, I cannot provide a definitive answer based on the FDA label data.[0m

[32mIn the absence of specific information from the FDA label data, the degree of reliability of the answer is low, and we cannot determine the degree of risk associated with BACTRIM in relation to hip [0m
[32mfractures.[0m

[1;32m<[0m[1;32mDONE[0m[1;32m>[0m[32m DO-NOT-KNOW[0m

[32mThe justification for this answer is that the FDA label data, as provided by FDAHandler, does not specify whether BACTRIM increases or decreases the risk of hip fracture, and therefore we do not have [0m
[32mreliable information to answer the question.[0m
